immunomodulation

Type: Keyphrase
Name: immunomodulation
First reported 19 hours ago - Updated 19 hours ago - 1 reports

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of ...

Histone deacetylase (HDAC) inhibitors are a class of agents that have potent antitumor activity with a reported ability to upregulate MHC and costimulatory molecule expression. We hypothesized that epigenetic pharmacological immunomodulation could sensitize ... [Published 7thSpace - 19 hours ago]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Public Health News Roundup: April 14

Study: Mean Devices Approved for Pediatric Use Never Tested on KidsThe majority of medical devices recently approved for pediatric use were never actually tested on kids, but rather only on people ages 18 and older, according to a new study in the journal ... [Published RWJF - Apr 14 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

ImmuPharma to sponsor Athens lupus conference

Drug discovery group ImmuPharma ( LON:IMM ) has announced it is sponsoring European Lupus Conference, in Athens later this month. Taking place between April 23 and 26, it is one of the major forums for people interested in the chronic autoimmune disease. ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Routine blood transfusions may decrease infection rates

Restrictive criteria for the use of routine blood transfusions in hospitals may help decrease infection rates in patients, according to a meta-analysis in The Journal of the American Medical Association.The study was led by Mary Rogers, Ph.D., from the ... [Published Campus Times - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Verastem Presents Data on Cancer Stem Cell-Targeting Agents at the 2014 AACR Annual Meeting

- 11:10 GMTVerastem Presents Data on Cancer Stem Cell-Targeting Agents at the2014 AACR Annual Meeting- Research Results Provide Additional Support for Targeting CancerStem Cells Directly and Through Immunomodulation of the TumorMicroenvironment –Verastem, ... [Published Mesothelioma News Today - Apr 10 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Disease Modification in Systemic Sclerosis

Descriptions of a systemic sclerosis (SSc)-like illness can be found in the writings of Hippocrates (460– 370 BC), however the first well-documented case was reported by Carlo Cursio in 1755. He described a 17-year-old female patient from Naples (Italy) ... [Published General Medicine eJournal - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

HSP60, HSP60 peptides and T cell vaccines for immunomodulation

The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment ... [Published Free Patents Online - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Donor Lymphocyte Infusion Improves Survival in Relapsed Lymphoma

Donor lymphocyte infusion (DLI) appears to improve the survival of patients with peripheral T cell lymphoma who have relapsed after undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).An abstract describing this research won the ... [Published American Journal of Public Health - Apr 08 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Studies from University of Rostock Have Provided New Data on Multiple Sclerosis

(NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Autoimmune Diseases and Disorders have been published. According to news reporting originating in Rostock, Germany, by NewsRx journalists, research stated, ... [Published NewsRX - Apr 04 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Recent Research from University of Virginia Highlight Findings in Immunotherapy

By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Data detailed on Biotechnology have been presented. According to news reporting out of Charlottesville, Virginia, by NewsRx editors, research stated, "This review discusses the current state ... [Published HispanicBusiness.com - Apr 02 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Angle appointments new Scientific Adviser

Angle (AIM: AGL), the specialist medtech company, has announced the appointment of Clive Stanway as Scientific Adviser with immediate effect.Dr Stanway ( pictured ) is currently Chief Scientific Officer of Cancer Research Technology (CRT), the technology ... [Published Pharma Letter - Mar 26 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

Immunological principles regulating immunomodulation with biomaterials

Source:Acta Biomaterialia, Volume 10, Issue 4Author(s): Tarik A. Khan , Sai T. ReddyThe immune system has evolved to recognize and eliminate pathogens; this recognition relies on the identification of structural molecular patterns within unique tissue ... [Published Bionity.com - Mar 20 2014]

Quotes

Image with caption: "Dr. Troy Harkness has received a Canadian Cancer Society Innovation Grant to investigate a new strategy to overcome treatment resistance in cancers. (CNW Group/Canadian Cancer Society (National Office))" . Image available at: http://photos.newswire.ca/images/download/20140416_C4010_PHOTO_EN_39331...
...said Brigham and Women's Hospital and Harvard Medical School research fellow Thomas J Hwang, one of the study’s authors, according to Reuters. "Without this data, it is difficult for clinicians and parents to make informed treatment decisions that weigh the risks and benefits of a particular treatment.” Read more on pediatrics ."
"In the balance of 2014 and 2015 we plan to add about 60 additional clinical centers to our study. With our new clinical research organizations, Ergomed and Aptiv Solutions, on board we are confident that we will meet our objective of completing patient enrollment by the end of 2015. We anticipate consistent month-over-month increases in the number of new patients enrolled" commented CEL-SCI Chief Executive Officer Geert Kersten
News editors obtained the following quote from the background information supplied by the inventors: "Nasopharyngeal carcinoma (NPC) arises from the epithelial cells of the nasopharynx and almost all nonkeratinizing and undifferentiated forms of the tumor are associated with Epstein Barr Virus (EBV) (Chan et al., 2002; Raab-Traub, 2002) NPC patients with limited local disease have a good prognosis when treated with chemotherapy and intensity-modulated radiation therapy, but the patients with bulky locoregional or metastatic disease often relapse or have refractory disease. (Chan et al., 2002; Mould and Tai, 2002; Ayan et al., 2003) Historical 5-year overall survival rates for those with advanced stage III or IV disease are reported between 54% to 76% and 29% to 56%, respectively. (Chan et al., 2002; Mould and Tai, 2002; Lee et al., 2010; Cooper, 1997) The patients who survive experience severe short-term and longterm morbidity, with an associated profound impact on their quality-of-life. (Wang et al., 2000; Louis et al., 2007) Hence, there is a need for novel therapies that both improve disease-free survival and reduce treatment-related complications."

More Content

All (97) | News (84) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Cancer Risk With Adalimumab in Crohn's Disease [Published General Medicine eJournal - 3 hours ago]
Canine cancer study aimed at improving survival... [Published Digital Journal - 3 hours ago]
Prolonged repeated vaccine immuno-chemotherapy ... [Published 7thSpace - 15 hours ago]
The histone deacetylase inhibitor, LBH589, prom... [Published 7thSpace - 19 hours ago]
Public Health News Roundup: April 14 [Published RWJF - Apr 14 2014]
CEL-SCI Reports March 2014 is Record Month for ... [Published Pharmacy Choice - Apr 14 2014]
On The Pulse - 11th April 2014 [Published OnMedicanet - Apr 11 2014]
ImmuPharma sponsors European Lupus Conference [Published Stock Market Wire - Apr 11 2014]
ImmuPharma to sponsor Athens lupus conference [Published Proactiveinvestors United Kingdom RSS feed - Apr 11 2014]
Routine blood transfusions may decrease infecti... [Published Campus Times - Apr 10 2014]
Researchers Submit Patent Application, "Ebv-Spe... [Published 4 Traders - Apr 10 2014]
Patent Issued for Cyclosporin Analogues [Published 4 Traders - Apr 10 2014]
Verastem Presents Data on Cancer Stem Cell-Targ... [Published Mesothelioma News Today - Apr 10 2014]
MORGAN STANLEY : Juno Therapeutics Appoints Bio... [Published 4 Traders - Apr 10 2014]
CEL-SCI Reports March 2014 is Record Month for ... [Published HispanicBusiness.com - Apr 10 2014]
Researchers Submit Patent Application, "Reversi... [Published HispanicBusiness.com - Apr 10 2014]
Kite Pharma Announces FDA Orphan Drug Designati... [Published HispanicBusiness.com - Apr 10 2014]
Disease Modification in Systemic Sclerosis [Published General Medicine eJournal - Apr 09 2014]
Quantity of red blood cells received linked to ... [Published Nurse.com - Apr 08 2014]
HSP60, HSP60 peptides and T cell vaccines for i... [Published Free Patents Online - Apr 08 2014]
Donor Lymphocyte Infusion Improves Survival in ... [Published American Journal of Public Health - Apr 08 2014]
Tau-Based Therapeutic Approaches for Alzheimer'... [Published Sexual Development - Apr 07 2014]
Biothera to Present Phase 2b NSCLC Data at ESMO... [Published Pharmacy Choice - Apr 07 2014]
Studies from Asahikawa Medical University Updat... [Published NewsRX - Apr 06 2014]
Study Results from Fujian Medical University in... [Published NewsRX - Apr 04 2014]
Studies from University of Rostock Have Provide... [Published NewsRX - Apr 04 2014]
"Adjuvanting Material" in Patent Application Ap... [Published 4 Traders - Apr 03 2014]
New Immunotherapy Study Findings Have Been Repo... [Published HispanicBusiness.com - Apr 02 2014]
Recent Research from University of Virginia Hig... [Published HispanicBusiness.com - Apr 02 2014]
Studies from AstraZeneca Yield New Information ... [Published 4 Traders - Apr 02 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Blocking B cells is not always good news for MS [Published Multiple Sclerosis Research - Mar 21 2014]
Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; for the ATAMS Study Group.  Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. ...
[Articles] Atacicept in multiple sclerosis (ATA... [Published The Lancet Neurology online - Mar 06 2014]
Increased clinical disease activity associated with atacicept suggests that the role of B cells and humoral immunity in multiple sclerosis is complex. For studies that explore therapeutic immunomodulation in multiple sclerosis, rigorous monitoring for ...
[Seminar] Cutaneous melanoma [Published The Lancet - Mar 01 2014]
In the past decade, major advances have been made in the understanding of melanoma. New predisposition genes have been reported and key somatic events, such as BRAF mutation, directly translated into therapeutic management. Surgery for localised melanoma ...
A Review of the Work of More of Last Year's Cla... [Published Fight Aging! - Feb 18 2014]
Young researchers intern each year at the SENS Research Foundation , doing their part to help advance the state of the art closer towards working rejuvenation treatments. The Foundation exists not just to coordinate and fund cutting edge research today ...
Yet another mechanism for glaterimer acetate [Published Multiple Sclerosis Research - Feb 03 2014]
From R, Eilam R, Bar-Lev DD, Levin-Zaidman S, Tsoory M, Lopresti P, Sela M, Arnon R, Aharoni R. Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate. Glia. 2014 Jan 30. doi: 10.1002/glia.22632. [Epub ahead of ...
1 2

Press Releases

sort by: Date | Relevance
arGEN-X and de Duve Institute/UCL to Collaborat... [Published Financial Services - Nov 04 2013]
aTyr Pharma Awarded Two Patents from USPTO to S... [Published PR Newswire - Aug 14 2013]
aTyr Pharma Expands Executive Leadership Team t... [Published PR Newswire - Aug 14 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.